Objective: To study whether exposure to childhood emotional, sexual or physical abuse is associated with subsequent multiple sclerosis (MS) development.
From the center
The Parkinson’s research program led by Prof. Charalampos Tzoulis at the Neuro-SysMed Center has been strengthened by grants from the regional and national Norwegian Health Authorities, amounting to more than 3 million Euros.
The grants will fund clinical studies led by Prof. Tzoulis’ group, including NOPARK.
NOPARK is a phase II, double-blinded randomized clinical trial of NAD-replenishment therapy by oral nicotinamide riboside (NR) in Parkinson’s disease. The trial will determine whether NR has neuroprotective action and delays the motor and non-motor progression of Parkinson’s disease. A total of 400 persons with Parkinson’s disease who have had the diagnosis for up to 2 years will be recruited from all of Norway.
Welcome to a CCBIO and Neuro-SysMed Special Seminar on Creativity & Innovation Leadership. Inspirational lectures and discussions with invited speakers Ole Dahlberg and Ingunn Johanne Ness.